Trial Profile
Study of the Effect of inhaled Short Acting Beta 2 Agonist(procaterol) on Breathlessness on Exertion in COPD patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Procaterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 27 Mar 2012 New trial record